![](/images/graphics-bg.png)
The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
Joint Authors
Dulley, Frederico Luiz
Bendit, Israel
Dias, Lucia
Conchon, Monika
Chamone, Dalton de Alencar Fischer
Dinardo, Carla Luana
Dorlhiac-Llacer, Pedro Enrique
Sanabani, Sabri S.
Source
Issue
Vol. 2009, Issue 2009 (31 Dec. 2009), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2009-10-22
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
We describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who underwent allogeneic bone marrow transplantation (alloBMT) at our institution over a period of 4 years.
Retrospective analysis of their medical records revealed that a mean age at transplant was 45.2 years.
The median time to diagnosis was 7.4 years after transplant.
At relapse, four, two, and one patients were classified as having hematologic, major molecular, and cytogenetic relapse, respectively.
At imatinib initiation, five had CML in a chronic phase, while one patient was diagnosed as having accelerated phase and blast crisis.
All these patients could be evaluated for the therapeutic efficacy.
At a mean of follow-up of 1.9 years of therapy, all evaluable patients achieved major molecular response without compromising safety.
Consistent with available data, our results indicate that imatinib is safe and effective treatment option for patients with relapse after BMT.
American Psychological Association (APA)
Conchon, Monika& Sanabani, Sabri S.& Bendit, Israel& Dinardo, Carla Luana& Dias, Lucia& Chamone, Dalton de Alencar Fischer…[et al.]. 2009. The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation،Vol. 2009, no. 2009, pp.1-4.
https://search.emarefa.net/detail/BIM-465489
Modern Language Association (MLA)
Conchon, Monika…[et al.]. The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation No. 2009 (2009), pp.1-4.
https://search.emarefa.net/detail/BIM-465489
American Medical Association (AMA)
Conchon, Monika& Sanabani, Sabri S.& Bendit, Israel& Dinardo, Carla Luana& Dias, Lucia& Chamone, Dalton de Alencar Fischer…[et al.]. The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. Journal of Transplantation. 2009. Vol. 2009, no. 2009, pp.1-4.
https://search.emarefa.net/detail/BIM-465489
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-465489